Rami Manochakian: Results of PALOMA3 study by Natasha B. Leighl et al

Rami Manochakian shared a post on X:

“Hot off the press.

Just published in Journal of Clinical Oncology (after presentation at ASCO24) Results of PALOMA3 study of Subcutaneous Vs Intravenous Amivantamab, in EGFR+ advanced non-small cell Lung Cancer.

Noninferior PK increased OS
Low Toxicity.”

Read further
Source: Rami Manochakian/X

Dr. Rami Manochakian is a thoracic medical oncologist at Mayo Clinic, Florida. He obtained his medical degree from the University of Aleppo in Syria before completing his Internal Medicine residency and chief residency at the University at Buffalo, NY. Dr. Manochakian further honed his expertise through a Hematology/Oncology fellowship and served as chief fellow at Case Western Reserve University, Cleveland, OH. Specializing in thoracic malignancies, including lung cancer, mesothelioma, and thymic tumors, he has dedicated his career to advancing the field of oncology.

Dr. Manochakian’s commitment to patient care extends beyond treatment, as he actively participates in clinical research to drive advancements in oncology. He is also recognized as a leader in medical education, serving in various educational and advisory roles at Mayo Clinic and national and international medical societies, including ASCO, ALA, and IASLC. Dr. Manochakian’s passion for education has earned him numerous awards and achievements, reflecting his dedication to training the next generation of oncologists. Through his tireless efforts, Dr. Manochakian continues to make significant contributions to cancer care, education, and research.